DOD announces the first patient enrolled for Phase 3 clinical trials for broad spectrum flu drug, Favipiravir
BioDefense Therapeutics (BD Tx)—a Joint Product Management office within the U.S. Department of Defense (DoD)—announced the first patient enrolled in the North American Phase 3 clinical trials for favipiravir More...